You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
More than 70 percent of labs surveyed experienced supply chain interruptions, forcing them to validate three or more diagnostic testing methods.
The group said the recommendations aim to standardize and improve warfarin response genotyping assays.
A pathologists' group has pointed out that the bill covers only EUA tests, and patients receiving tests with pending regulatory status may receive surprise bills.
The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.
The firm also recently released the results of collaborations with Admera Health and RareCyte that used its multiplex PCR-based target enrichment technology.
In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.
Frederick National Lab and Q2 Solutions have been validating the kit as early users and plan to implement it in their clinical trial services.
The research-use-only system, which has a list price of $299,000, fits with Thermo Fisher's vision of a future of disseminated implementation of NGS.
While some groups have communicated their concerns directly to the agency, stakeholders have also formed a new coalition to publicly take issue with FDA's actions.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program, but a Verily spokesperson says it currently working with multiple Bay Area counties.
The New York Times reports that developers in New York City are increasingly interested in life science spaces.
A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.
In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.